Cas:6264-69-3 4-bromobenzene-1,3-diamine manufacturer & supplier

We serve Chemical Name:4-bromobenzene-1,3-diamine CAS:6264-69-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

4-bromobenzene-1,3-diamine

Chemical Name:4-bromobenzene-1,3-diamine
CAS.NO:6264-69-3
Synonyms:4-Bromo-1,3-phenylenediamine;4-Brom-m-phenylendiamin;4-Brom-phenylendiamin-(1.3);4-bromo-m-phenylenediamine;4-Brom-1.3-diamino-benzol;1.3-Diamino-4-brom-benzol
Molecular Formula:C6H7BrN2
Molecular Weight:187.03700
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:298.8ºC at 760 mmHg
Density:1.697g/cm3
Index of Refraction:1.696
PSA:52.04000
Exact Mass:185.97900
LogP:2.77590

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 4-Bromo-1,3-phenylenediamine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1.3-Diamino-4-brom-benzol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-Brom-1.3-diamino-benzol Use and application,4-Bromo-1,3-phenylenediamine technical grade,usp/ep/jp grade.


Related News: Stevanato’s been out of start-up mode for a while: The firm doubled its net profit to $94 million in 2020 on $779 million in revenues, which were up 23% from 2019. That strong growth in sales helped place Sergio Stevanato, 79, Giovanni’s son and the company’s chairman emeritus, on Forbes’ World’s Billionaires list for the first time in 2021, with a net worth of $1.9 billion. (11β,17α-Dihydroxy-4-pregnene-3,20-dion-21-yl-21-thio)acetic acid manufacturers For these reasons, many pharmaceutical companies are choosing to evaluate biocatalytic processes during early-stage drug development to avoid missing opportunities for capitalizing on these gains. Thymulin (swine peptide moiety), 7-deglycine- suppliers In 2021, the combo has raked in $818 million in the first half of the year alone for Novartis, a number that is already up 11% from last year. Comparatively, Roche reported $218 million in sales of Zelboraf in 2016, and revenue was not reported in its most recent mid-year update. Cytochrome b (Panthera tigris haplotype COR7 mitochondria-encodedgene CytB fragment) vendor & factory.